BALDRY MARK (Chief Commercial Officer) purchased 37.2% of their position (35.05K shares) of X4 PHARMACEUTICALS, INC on the open market
Open‑market purchase worth $19.3K — a major conviction buy. The strongest form of insider conviction signal.
P · 2 purchases
Filed: 2/14/2025ACC: 0001628280-25-005698
Officer· Chief Commercial Officer
Since Nov 2022
+635.05K
Net shares
Net buyer
$19.3K
Total acquired
2
Open market trades
2B · 0S
3
Total transactions
635.05K acquired
Non-Derivative Transactions3
Common Stock
Direct
Shares
+21.65K
Price / share
$0.68
Trade value
$14.65K
% of position
23.0%
5/17/2024
94.12K→115.77K
Common Stock
Direct
Shares
+13.40K
Price / share
$0.34
Trade value
$4.60K
% of position
11.6%
11/15/2024
115.77K→129.17K
Common Stock
Direct
Shares
+600K
Price / share
—
Trade value
—
% of position
464.5%
2/12/2025
129.17K→729.17K
Total
Net shares
+635.05K
Net value
$19.25K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 5/17/2024 | P · Purchase | +21.65K | $0.68 | $14.65K | 23.0% | 94.12K | 115.77K |
| Common Stock Direct | 11/15/2024 | P · Purchase | +13.40K | $0.34 | $4.60K | 11.6% | 115.77K | 129.17K |
| Common Stock Direct | 2/12/2025 | A · Award | +600K | — | — | 464.5% | 129.17K | 729.17K |
| Total | +635.05K | $19.25K | ||||||
Derivative Transactions0
No derivative transactions reported